UNASSIGNED: In the prospective, multicenter Onyx ONE (One-Month DAPT) Clear study, 1506 patients at HBR treated with a ZES that discontinued DAPT at 30 days were included. The clinical outcomes of patients undergoing treatment of lesions with an RVD of ≤2.5 mm (SVD group, as determined by the angiographic core laboratory) were compared with patients without SVD. The primary end point was the composite of cardiac death or myocardial infarction between 1 and 12 months.
UNASSIGNED: Small vessel diameter treatment was performed in 489 (32.5%) patients. Patients with SVD were more likely to be women, have undergone a previous percutaneous intervention, and have multivessel coronary artery disease than patients without SVD. There were no significant differences in lesion, device, or procedural success between the groups. The Kaplan-Meier rate estimate of the primary end point was 8.5% and 6.8% in patients with SVD and those without SVD, respectively (P = .425). No significant differences were found in any secondary end point. The Kaplan-Meier rate of stent thrombosis was 0.6% and 0.8% in patients with SVD and those without SVD, respectively (P = .50).
UNASSIGNED: Among patients at HBR treated with a ZES and 1-month DAPT, those with SVD had favorable 12-month ischemic and bleeding outcomes, which were comparable with those of patients with larger caliber vessels.
■在未来,多中心OnyxONE(一个月DAPT)清除研究,纳入了在30天停止DAPT的ZES治疗的HBR患者1506例。RVD≤2.5mm(SVD组,由血管造影核心实验室确定)与无SVD的患者进行比较。主要终点是1至12个月之间的心脏死亡或心肌梗死的复合终点。
■对489例(32.5%)患者进行了小血管直径治疗。SVD患者更可能是女性,之前经历过经皮介入,与没有SVD的患者相比,患有多支冠状动脉疾病。病变无显著差异,装置,或组间程序上的成功。SVD患者和无SVD患者的主要终点Kaplan-Meier率估计分别为8.5%和6.8%。分别(P=.425)。在任何次要终点均未发现显着差异。SVD患者和无SVD患者的Kaplan-Meier支架内血栓形成率分别为0.6%和0.8%,分别(P=.50)。
■在接受ZES和1个月DAPT治疗的HBR患者中,SVD患者12个月缺血和出血结局良好,与较大口径血管的患者相当。